IN8bio to Present at ISCT 2024

IN8bio, Inc., a biopharmaceutical company at the clinical stage, has announced that it will make several presentations at the International Society for Cell & Gene Therapy (ISCT) 2024. The event is scheduled to take place from May 28th to June 1st in Vancouver, Canada. Dr. Kate Rochlin, Chief Operating Officer of IN8bio, highlighted the significance of ISCT as a platform for groundbreaking ideas and innovations in cellular therapies. She pointed out that their presentations would showcase meaningful advances in their proprietary gamma-delta T cell therapies.

Dr. Rochlin noted that the company would demonstrate how their unique manufacturing processes influence the characteristics of their cellular products, enabling the consistent production of a robust final product. This advancement is crucial for the development of IN8bio's DeltEx gamma-delta T cell platform, which has led to several investigational candidates now progressing into multi-center Phase 2 clinical trials. These trials are designed to target and potentially eradicate cancer cells, aiming to improve patient outcomes.

The scheduled poster presentations are as follows:

1. INB-400 DeltEx Drug Resistant Immunotherapy (DRI) Multi-Center Clinical Trial Product Logistics Management
- Poster Number: 816
- Session: Poster Networking Reception #1
- Date/Time: May 29th, 7 pm - 8:30 pm PDT
- Presenter: Guoling Chen, Senior Director Quality Operations, IN8bio

2. Healthy Donor vs. Patient Manufactured Autologous DeltEx DRI Product; TCR Repertoire Sequencing
- Poster Number: 850
- Date/Time: May 29th, 7 pm - 8:30 pm PDT
- Session: Poster Networking Reception #1
- Presenter: Mariska ter Haak, Senior Director Analytical Development, IN8bio

IN8bio specializes in developing gamma-delta T cell-based immunotherapies for cancer. Gamma-delta T cells have unique properties that allow them to distinguish between healthy and diseased tissues. The company's leading program, INB-400, is currently in a Phase 2 trial for glioblastoma multiforme (GBM). Additionally, the company has Phase 1 trials underway for both solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation.

The press release also contained forward-looking statements, indicating ambitious goals and expectations for IN8bio's future developments. These statements are identified by terms that suggest projections about future events, such as "aims," "anticipates," and "expects." It was emphasized that actual results could vary significantly due to various factors, including the complexities and uncertainties associated with clinical trials, regulatory approvals, and reliance on third parties for development and research activities.

IN8bio warned that the plans and intentions described might not materialize as expected, and the outcomes could differ due to numerous risk factors. These include the uncertainties inherent in preclinical studies and clinical trials, potential adverse effects, and the reliance on third-party collaborations.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!